Home > Press Releases > Announcement on Completion of Transfer of Manufacturing and Marketing Approval of Zomig® Tablets 2.5 mg and Zomig® RM Tablets 2.5 mg, Migraine Treatment
Announcement on Completion of Transfer of Manufacturing and Marketing Approval of Zomig® Tablets 2.5 mg and Zomig® RM Tablets 2.5 mg, Migraine Treatment
This website uses cookies to improve your experience and analyze site traffic. You can read more about our cookie and privacy policy by clicking here. Accept
